Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2010

View Archived Issues

MerLion Pharmaceuticals discloses novel antibacterial agents

Novel antiviral compounds disclosed by U.S. scientists

NeuroSearch claims new ligands of nicotinic acetylcholine and monoamine receptors

NeuroSearch discovers novel monoamine reuptake inhibitors

Novel NS5B inhibitors for treatment of HCV infections claimed by Italian scientists

Single- and repeat-dose studies encourage further evaluation of ACU-4429 in AMD

Favorable preclinical safety of bispecific MM-111 antibody for HER2-positive solid tumors disclosed

Promising preclinical safety profile of new tenofovir analogue CMX-157 disclosed

Novel HIV maturation inhibitor MPI-0461359 developed at Myriad Pharmaceuticals

Second-generation cholesterol absorption inhibitors discovered at Merck & Co.

RAMBO; a new oncolytic viral therapeutic approach with potent preclinical activity

Arrayit appoints DOCRO to facilitate FDA approval of OvaDx ovarian cancer test

Syngene to collaborate with Endo to develop anticancer molecules

Cumberland submits Acetadote sNDA for acute liver failure to FDA

GSK resubmits Avodart sNDA for prostate cancer to FDA

Cephalon receives complete response letter from FDA for Nuvigil

Pearl presents phase I data on PT-003 for chronic obstructive pulmonary disease

FDA accepts for review Savient's resubmitted Krystexxa BLA

Immunovaccine Technologies begins enrollment in phase I trial of DPX-0907 cancer vaccine

Trius reports phase I data on intravenously dosed antibacterial torezolid

Clinical Data reports results of phase I Stedivaze studies

MMRF grants awards to Intellikine and Tragara for multiple myeloma therapies

Ascent Therapeutics changes name to Anchor Therapeutics

Dicerna and Ipsen enter into exclusive research collaboration

Alcon completes acquisition of Durezol and Zyclorin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...